Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

8 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Investigation after 24 Wochen (T8) VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Investigation after 24 Wochen (T8), provided that a 3 week interval existed

- 13/09/16 - 1 modulo, 1 ItemGroup, 36 elementi, 1 linguaggio
ItemGroup: Laboratory parameters
Study documentation part: Investigation after 24 Wochen (T8), VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

Investigation after 21 weeks (T7) VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Investigation after 21 weeks (T7), provided that a 3 week interval existed

- 13/09/16 - 1 modulo, 1 ItemGroup, 37 elementi, 1 linguaggio
ItemGroup: Laboratory parameters
Study documentation part: Investigation after 21 weeks (T7), VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

Investigation after 18 or 24 weeks (T6) VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Investigation after 18 or 24 weeks (T6)

- 13/09/16 - 1 modulo, 1 ItemGroup, 37 elementi, 1 linguaggio
ItemGroup: Laboratory parameters
Study documentation part: Investigation after 18 or 24 weeks (T6), VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

Investigation after 12 or 16 weeks (T4) VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Investigation after 12 or 16 weeks (T4)

- 13/09/16 - 1 modulo, 1 ItemGroup, 37 elementi, 1 linguaggio
ItemGroup: Laboratory parameters
Study documentation part: Investigation after 12 or 16 weeks (T4), VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

Investigation after 15 or 20 weeks (T5) VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Investigation after 15 or 20 weeks (T5)

- 13/09/16 - 1 modulo, 1 ItemGroup, 37 elementi, 1 linguaggio
ItemGroup: Laboratory parameters
Study documentation part: Investigation after 15 or 20 weeks (T5), VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

Investigation after 6 or 8 weeks (T2) VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Investigation after 6 or 8 weeks (T2)

- 13/09/16 - 1 modulo, 1 ItemGroup, 37 elementi, 1 linguaggio
ItemGroup: Laboratory parameters
Study documentation part: Investigation after 6 or 8 weeks (T2), VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

Investigation after 3 or 4 weeks (T1) VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Investigation after 3 or 4 weeks (T1)

- 13/09/16 - 1 modulo, 1 ItemGroup, 37 elementi, 1 linguaggio
ItemGroup: Laboratory parameters
Study documentation part: Investigation after 3 or 4 weeks (T1), VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

Investigation after 9 or 12 weeks (T3) VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Investigation after 9 or 12 weeks (T3)

- 13/09/16 - 1 modulo, 1 ItemGroup, 37 elementi, 1 linguaggio
ItemGroup: Laboratory parameters
Study documentation part: Investigation after 9 or 12 weeks (T3), VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial